Ikarian Capital’s aTyr Pharma ATYR Stock Holding History

Ikarian Capital’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-925	Closed	-$197K	–	210
2022 Q1	$197K	Buy	925 +49	+6%	+$11.1K	0.03%	168
2021 Q4	$262K	Sell	876 -13,180	-94%	-$4.4M	0.04%	152
2021 Q3	$5.1M	Buy	14,056 +6,556	+87%	+$1.57M	0.36%	64
2021 Q2	$1.46M	Hold	7,500	–	–	0.12%	147
2021 Q1	$1.34M	Sell	7,500 -2,500	-25%	-$470K	0.05%	227
2020 Q4	$1.55M	Buy	+10,000	New	+$1.46M	0.07%	165

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ikarian Capital's ATYR Position: Q2 2022 in Review

Ikarian Capital sold out of aTyr Pharma (ATYR) in Q2 2022, closing a stake of 925 shares — an estimated $197K sold.

Ikarian Capital first reported a position in ATYR in Q4 2020 and held it in 6 quarters. The position peaked at $5.1M in Q3 2021. 36 funds tracked by Wall St. Rank hold ATYR as of Q2 2022.

Ikarian Capital reported no remaining aTyr Pharma position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 925 aTyr Pharma shares in Q2 2022, an estimated $197K.
Ikarian Capital first reported a position in aTyr Pharma in Q4 2020 and held it in 6 quarters.
Ikarian Capital's aTyr Pharma position peaked at $5.1M in Q3 2021.
36 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.